A Clinical Registry to Demonstrate the Safety and Performance of Teleflex Vascular Access Devices
Recruiting · NCT06604039
Conditions: Vascular Access Device
At a glance
- Research payments reported, 2025
- $70,086
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 2,500
About the trial
- Sponsor
- Teleflex
- Tested
- Central venous catheter (device)
- Dates
- Started 2024-12-08; completion 2034-12-07
- Results posted
- Not yet
The objective of Teleflex's Vascular Access Device Registry (VADER) is to provide high-quality data on the performance, safety, and clinical benefits of Teleflex's vascular access devices when used in a real-world setting
From ClinicalTrials.gov, last updated 2026-10-07. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Teleflex LLC reported $70,086 in research payments for this study in 2025 (14 payments).
Products named: Arrow
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Sara E. Couey, CRNP Nurse Practitioners · Athens, AL
- Melissa D. Mccabe, MD, MSCR Anesthesiology · Loma Linda, CA
- Haval Chweich, M.D Critical Care Medicine · Boston, MA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Loma Linda University Medical Center, CA $37,611
- Tufts Medical Center, MA $19,500
- Huntsville Hospital $12,975
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.